Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 29 Feb 2024
Collaborating to help improve access to drugs for rare diseases
29 February 2024 - On Rare Disease Day — a day when the international community raises awareness about rare conditions ...
Posted by Michael Wonder on 29 Feb 2024
Schedule of Pharmaceutical Benefits - 1 March 2024
1 March 2024 - The March 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 29 Feb 2024
Indapta Therapeutics receives US FDA fast track designation for lead clinical drug candidate IDP-023 for non-Hodgkin’s lymphoma and myeloma
29 February 2024 - Highly differentiated allogeneic natural killer cell therapy in Phase 1 trial, with initial data expected in second ...
Posted by Michael Wonder on 29 Feb 2024
House looks to weaken Medicare negotiation
29 February 2024 - Two proposals to weaken Medicare’s drug price negotiation program are getting a hearing before a House Energy ...
Posted by Michael Wonder on 29 Feb 2024
Regulator acts to close loophole enabling Australian pharmacists to make copycat Ozempic drug
29 February 2024 - The TGA will move to ban compounding pharmacists from making their own versions of injectable weight ...
Posted by Michael Wonder on 29 Feb 2024
New Zealand Pharmaceutical Schedule - 1 March 2024
1 March 2024 - The March 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 29 Feb 2024
Today is Rare Disease Day
29 February 2024 - PHARMAC understands that people living with rare disorders face many challenges, including access to health care ...
Posted by Michael Wonder on 29 Feb 2024
Added benefit and revenues of oncology drugs approved by the EMA between 1995 and 2020: retrospective cohort study
28 February 2024 - Added benefit was evaluated using ratings published by seven organisations: health technology assessment agencies from the US, ...
Posted by Michael Wonder on 28 Feb 2024
MSAC publishes agenda for Jun 2024 ESC meeting
28 February 2024 - The MSAC Secretariat has published a list of applications scheduled to be considered by the ESC ...
Posted by Michael Wonder on 28 Feb 2024
Bernie Sanders wants to rein in drug prices. Is he asking the right questions?
28 February 2024 - We have a serious problem of affordability of health care in the US, including the cost of ...
Posted by Michael Wonder on 28 Feb 2024
Applied Therapeutics announces FDA acceptance and priority review of new drug application for govorestat for the treatment of classic galactosaemia
28 February 2024 - PDUFA target action date of 28 August 2024. ...
Posted by Michael Wonder on 28 Feb 2024
Incyte announces US FDA grants priority review for axatilimab for the treatment of chronic graft versus host disease
27 February 2024 - Priority review acceptance based on positive results of AGAVE-201 study. ...
Posted by Michael Wonder on 28 Feb 2024
AB Science announces that Health Canada has issued a notice of non-compliance-withdrawal for masitinib in ALS
26 February 2024 - AB Science today announces that Health Canada has issued a notice of non-compliance-withdrawal regarding its new ...
Posted by Michael Wonder on 28 Feb 2024
Minister announces parallel assessment means new medicines assessed sooner
28 February 2024 - PHARMAC is changing its process so it can assess a funding application at the same time Medsafe ...
Posted by Michael Wonder on 28 Feb 2024
The FDA isn’t afraid to yank a disappointing drug
26 February 2024 - The FDA is rescinding its approval of a blood cancer treatment from the Swedish firm Oncopeptides, ...